Raymond James Financial Services Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-12,538
| Closed | -$13.4K | – | 3422 |
|
|
2023
Q3 | $13.4K | Sell |
12,538
-797
| -6% | -$853 | ﹤0.01% | 3192 |
|
|
2023
Q2 | $34.5K | Sell |
13,335
-22,072
| -62% | -$57.2K | ﹤0.01% | 3144 |
|
|
2023
Q1 | $144K | Sell |
35,407
-18,020
| -34% | -$73.5K | ﹤0.01% | 2987 |
|
|
2022
Q4 | $268K | Sell |
53,427
-31,459
| -37% | -$158K | ﹤0.01% | 2663 |
|
|
2022
Q3 | $1.11M | Buy |
84,886
+22,199
| +35% | +$290K | ﹤0.01% | 1746 |
|
|
2022
Q2 | $804K | Buy |
62,687
+33,596
| +115% | +$431K | ﹤0.01% | 1968 |
|
|
2022
Q1 | $444K | Buy |
+29,091
| New | +$444K | ﹤0.01% | 2453 |
|
|
2020
Q4 | – | Sell |
-14,057
| Closed | -$224K | – | 3041 |
|
|
2020
Q3 | $224K | Sell |
14,057
-2,197
| -14% | -$35K | ﹤0.01% | 2460 |
|
|
2020
Q2 | $321K | Buy |
+16,254
| New | +$321K | ﹤0.01% | 2186 |
|